Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

Blueprint plots return to FDA with new Ayvakit data in rare condition — and the analysts cheer

Source: 
Endpoints
snippet: 

Over a decade after launch, Blueprint Medicines nabbed the first approval for their first drug earlier this year. Now, as they move forward with a Roche-partnered global launch, they’re touting data that could push them into more patients.